Literature DB >> 33563949

Proteomic and functional analyses in disease models reveal CLN5 protein involvement in mitochondrial dysfunction.

Stefano Doccini1, Federica Morani1, Claudia Nesti1, Francesco Pezzini2, Giulio Calza3, Rabah Soliymani3, Giovanni Signore4,5, Silvia Rocchiccioli6, Katja M Kanninen7, Mikko T Huuskonen7, Marc H Baumann3, Alessandro Simonati8, Maciej M Lalowski9, Filippo M Santorelli10.   

Abstract

CLN5 disease is a rare form of late-infantile neuronal ceroid lipofuscinosis (NCL) caused by mutations in the CLN5 gene that encodes a protein whose primary function and physiological roles remains unresolved. Emerging lines of evidence point to mitochondrial dysfunction in the onset and progression of several forms of NCL, offering new insights into putative biomarkers and shared biological processes. In this work, we employed cellular and murine models of the disease, in an effort to clarify disease pathways associated with CLN5 depletion. A mitochondria-focused quantitative proteomics approach followed by functional validations using cell biology and immunofluorescence assays revealed an impairment of mitochondrial functions in different CLN5 KO cell models and in Cln5-/- cerebral cortex, which well correlated with disease progression. A visible impairment of autophagy machinery coupled with alterations of key parameters of mitophagy activation process functionally linked CLN5 protein to the process of neuronal injury. The functional link between impaired cellular respiration and activation of mitophagy pathways in the human CLN5 disease condition was corroborated by translating organelle-specific proteome findings to CLN5 patients' fibroblasts. Our study highlights the involvement of CLN5 in activation of mitophagy and mitochondrial homeostasis offering new insights into alternative strategies towards the CLN5 disease treatment.

Year:  2020        PMID: 33563949     DOI: 10.1038/s41420-020-0250-y

Source DB:  PubMed          Journal:  Cell Death Discov        ISSN: 2058-7716


  50 in total

1.  Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1/2 study.

Authors:  Anu Cherukuri; Heather Cahan; Greg de Hart; Andrea Van Tuyl; Peter Slasor; Laurie Bray; Joshua Henshaw; Temitayo Ajayi; Dave Jacoby; Charles A O'Neill; Becky Schweighardt
Journal:  Clin Immunol       Date:  2018-09-08       Impact factor: 3.969

2.  Cln5-deficiency in mice leads to microglial activation, defective myelination and changes in lipid metabolism.

Authors:  Mia-Lisa Schmiedt; Tea Blom; Tomas Blom; Outi Kopra; Andrew Wong; Carina von Schantz-Fant; Elina Ikonen; Mervi Kuronen; Matti Jauhiainen; Jonathan D Cooper; Anu Jalanko
Journal:  Neurobiol Dis       Date:  2011-12-13       Impact factor: 5.996

3.  Involvement of the mitochondrial compartment in human NCL fibroblasts.

Authors:  Francesco Pezzini; Floriana Gismondi; Alessandra Tessa; Paola Tonin; Rosalba Carrozzo; Sara E Mole; Filippo M Santorelli; Alessandro Simonati
Journal:  Biochem Biophys Res Commun       Date:  2011-11-11       Impact factor: 3.575

4.  Study of Intraventricular Cerliponase Alfa for CLN2 Disease.

Authors:  Angela Schulz; Temitayo Ajayi; Nicola Specchio; Emily de Los Reyes; Paul Gissen; Douglas Ballon; Jonathan P Dyke; Heather Cahan; Peter Slasor; David Jacoby; Alfried Kohlschütter
Journal:  N Engl J Med       Date:  2018-04-24       Impact factor: 91.245

Review 5.  Genetics of the neuronal ceroid lipofuscinoses (Batten disease).

Authors:  Sara E Mole; Susan L Cotman
Journal:  Biochim Biophys Acta       Date:  2015-05-27

6.  Phenotype and natural history of variant late infantile ceroid-lipofuscinosis 5.

Authors:  Alessandro Simonati; Ruth E Williams; Nardo Nardocci; Minna Laine; Roberta Battini; Angela Schulz; Barbara Garavaglia; Francesca Moro; Francesco Pezzini; Filippo M Santorelli
Journal:  Dev Med Child Neurol       Date:  2017-05-25       Impact factor: 5.449

7.  A mouse model for Finnish variant late infantile neuronal ceroid lipofuscinosis, CLN5, reveals neuropathology associated with early aging.

Authors:  Outi Kopra; Jouni Vesa; Carina von Schantz; Tuula Manninen; Helena Minye; Anna-Liisa Fabritius; Juhani Rapola; Otto P van Diggelen; Janna Saarela; Anu Jalanko; Leena Peltonen
Journal:  Hum Mol Genet       Date:  2004-09-30       Impact factor: 6.150

8.  The mouse ortholog of the neuronal ceroid lipofuscinosis CLN5 gene encodes a soluble lysosomal glycoprotein expressed in the developing brain.

Authors:  Ville Holmberg; Anu Jalanko; Juha Isosomppi; Anna-Liisa Fabritius; Leena Peltonen; Outi Kopra
Journal:  Neurobiol Dis       Date:  2004-06       Impact factor: 5.996

9.  Proteomic Profiling in the Brain of CLN1 Disease Model Reveals Affected Functional Modules.

Authors:  Saara Tikka; Evanthia Monogioudi; Athanasios Gotsopoulos; Rabah Soliymani; Francesco Pezzini; Enzo Scifo; Kristiina Uusi-Rauva; Jaana Tyynelä; Marc Baumann; Anu Jalanko; Alessandro Simonati; Maciej Lalowski
Journal:  Neuromolecular Med       Date:  2015-12-26       Impact factor: 3.843

10.  Drafting the CLN3 protein interactome in SH-SY5Y human neuroblastoma cells: a label-free quantitative proteomics approach.

Authors:  Enzo Scifo; Agnieszka Szwajda; Janusz Dębski; Kristiina Uusi-Rauva; Tapio Kesti; Michał Dadlez; Anne-Claude Gingras; Jaana Tyynelä; Marc H Baumann; Anu Jalanko; Maciej Lalowski
Journal:  J Proteome Res       Date:  2013-04-19       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.